Company / Current Liabilities
CRISPR Therapeutics AG Current Liabilities History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Liabilities
$149.1M
FY2025
5-year range
$87.8M / $149.1M
FY2021-FY2025
Trend
+69.9%
vs FY2024
Sector context
#72 of 215
Health Care
What the data says
At $149M, CRISPR Therapeutics AG's current liabilities ranks #144 of 215 in the Health Care sector. Current Liabilities returned to growth in FY2025 after 2 years of decline, reaching $149M.
Based on SEC 10-K filings.
$149M in FY2025 with a 5-year CAGR of +9.6%.
Increased from $109M to $149M over the past 2 years.
Health Care sector context is included.
Current Liabilities over time
Growth rates
- 3-Year CAGR
- +7.2%
- 5-Year CAGR
- +9.6%
- 10-Year CAGR
- -
Sector benchmark
#144 of 215 in Health CareTop 67% of 215This company $149.1M Sector average $1.6B
▼
-90.5% below sector average
Key checks
Key Insights
- 5-year CAGR of +9.6%, indicating consistent growth.
- In FY2025, current liabilities increased 69.9% year-over-year.
- Ranks #72 out of 215 companies in the Health Care sector.
- Lowest current liabilities in the period was in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current LiabilitiesValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $149.1M | +69.9% |
| FY2024 | $87.8M | -19.3% |
| FY2023 | $108.8M | -10.2% |
| FY2022 | $121.1M | +1.0% |
| FY2021 | $119.9M | +27.2% |
| FY2020 | $94.3M | +65.1% |
| FY2019 | $57.1M | +105.8% |
| FY2018 | $27.7M | +91.2% |
| FY2017 | $14.5M | -34.0% |
| FY2016 | $22.0M | +116.6% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026